Johnson & Johnson's Tremfya Approved by EC for Ulcerative Colitis Treatment
CompanyDrug

Johnson & Johnson’s Tremfya Approved by EC for Ulcerative Colitis Treatment

Keymed Biosciences Gains NMPA Approval for Phase I/II Study of CM518D1
CompanyDrug

Keymed Biosciences Gains NMPA Approval for Phase I/II Study of CM518D1

Akeso's Ivonescimab Approved by NMPA for First-Line PD-L1-Positive NSCLC
CompanyDrug

Akeso’s Ivonescimab Approved by NMPA for First-Line PD-L1-Positive NSCLC

Explore the latest insights on Lifeon Pharmaceutical and its impact on China's pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Lifeon Pharmaceutical's developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.
CompanyDrug

Hefei Lifeon Gains NMPA Approval for Nexletol Clinical Trials in China

Fujian Cosunter Gains NMPA Clearance for Phase II HBV Study of GST-HG131 and GST-HG141
CompanyDrug

Fujian Cosunter Gains NMPA Clearance for Phase II HBV Study of GST-HG131 and GST-HG141

Anhui Anke's Allogeneic CAR-T Therapy UTAA09 Approved for r/r B-ALL Trials
CompanyDrug

Anhui Anke’s Allogeneic CAR-T Therapy UTAA09 Approved for r/r B-ALL Trials

Juventas Cell Therapy's CNCT 19 Gains NMPA Approval for Refractory Lupus Nephritis
CompanyDrug

Juventas Cell Therapy’s CNCT 19 Gains NMPA Approval for Refractory Lupus Nephritis

TYK Medicines Submits Pre-NDA Package for Asandeutertinib in NSCLC Brain Metastasis
CompanyDrug

TYK Medicines Submits Pre-NDA Package for Asandeutertinib in NSCLC Brain Metastasis

MicroPort Scientific's MRI-Conditional ALIZEA Hybrid Pacing System Secures CE Certification
CompanyMedical Device

MicroPort Scientific’s MRI-Conditional ALIZEA Hybrid Pacing System Secures CE Certification

AbbVie Files BLA for TrenibotE in Moderate to Severe Glabellar Lines Treatment
CompanyDrug

AbbVie Files BLA for TrenibotE in Moderate to Severe Glabellar Lines Treatment

GenFleet's KRAS G12D Inhibitor GFH375/VS-7375 Gains FDA Trial Approval
CompanyDrug

GenFleet’s KRAS G12D Inhibitor GFH375/VS-7375 Gains FDA Trial Approval

Innate Pharma and Sanofi Restructure 2016 Research Agreement on CD123 ANKET Drug
CompanyDeals

Innate Pharma and Sanofi Restructure 2016 Research Agreement on CD123 ANKET Drug